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Tetracycline fluorescence in uremic and primary hyperparathy-
roid bone. Twenty-five patients with end-stage renal disease, nine
of whom were receiving pharmacologic doses of vitamin D, and
seventeen patients with primary hyperparathyroidism underwent
bone biopsy following a three-day course of tetracycline adminis-
tration. The mean width of the fluorescent tetracycline bands were
significantly greater in the bones of patients with uremia than in
those with primary hyperparathyroidism. This difference was due
to wide labels present in the patients with uremia who had not
been treated with vitamin D, as no differences existed in mean
label widths of patients with uremia who had received this com-
pound and the patients with primary hyperparathyroidism. Com-
parison of the maximum label widths distinguished not only prima-
ty hyperparathyroid patients from those with uremia, but uremic
patients who had recieved vitamin D from those who had not been
so treated. Quantitative microscopy of standard, nonfluorescent
histologic features failed to make this latter distinction. These data
are consistent with the presence of a wide zone of instantaneously
fluorescing material in uremic bone following tetracycline adminis-
tration, which does not relate to bone apposition occurring during
antibiotic administration. This phenomenon probably represents a
delay in mineral maturation which is normalized by vitamin D.
Furthermore, it is apparent that the use of a continuously adminis-
tered (single) tetracycline label will result in an overestimation of
bone formation rates, particularly in osteomalacic states.
Fluorescence de Ia tetracycline dans l'os an cours de
l'hyperparathyroIdisme uremique on primaire. Vingt-cinq
malades atteints d'insuffisance rénale terminale, dont neuf rece-
vaient des doses pharmacologiques de vitamine D, et dix-sept
malades atteints d'hyperparathyroIdie primaire, ont subi une biop-
sie osseuse après l'administration de tetracycline pendant trois
jours. La largeur nioyenne des bandes de fluorescence de Ia
tetracycline est signiflcativemcnt plus grande dans l'os de malades
urémiques que dans celui de malades atteints d'hyperparathyroIdie
primaire. Cette difference est due aux marques larges qui existent
chez les malades urémiques qui n'ont pas été traités par Ia vita-
mine D. En effet, ii ny a pas de difference entre Ia largeur des
marquages chez les urémiques traités par Ia vitamine D et les
malades atteints d'hyperparathyroidisme primaire. La comparai-
son des largeurs maximales ne différencie pas seulement
l'hyperparathyroidisme primaire de l'urémie, mais encore les uré-
mies traitées par Ia vitamine D de celles qui ne l'ont pas été. La
microscopie quantitative des caractères habituels ne comprenant
pas Ia fluorescence, ne peut pas faire une telle differentiation. Ces
iésultats concordent avec Ia presence dans I'os, au cours de
l'urémie, d'une large zone de materiel immediatement fluorescent
apres l'administration de tetracycline qui ne traduit pas une appo-
sition osseuse qui surviendrait au cours de l'administration de
l'antibiotique. Ce phenomene représente probablement un retard
de Ia maturation minérale, retard qui est corrige par Ia vitamine D.
II apparait, de plus. que l'emploi d'un marquage par Ia tetracycline
administrée de facon continue aboutit a une surestimation de Ia
vitesse deformation de Ios, surtout au cours des osteomalacies.
Since the discovery of tetracycline-induced fluo-
rescence in bone [1], the study of human skeletal
tissue has had the unique advantage of a nontoxic,
tissue time-marker which may be used to obtain
meaningful kinetic data by morphologic means [2].
The fundamental assumption underlying many such
histomorphometric studies is that the quantity of
fluorescent tissue produced during administration of
the antibiotic reflects net bone mineralization which
has occurred during that period [3—8].
As a result of a previous study performed in this
laboratory [9], we became interested in the degree to
which the total quantity of tetracycline fluorescence
in lamellar bone may not represent time-related
bone synthesis. We have therefore examined the
widths of fluorescent labels following tetracycline
administered over a short period of time to a group of
patients with end-stage renal disease or primary
hyperparathyroidism. The significant differences in
label width between these groups may be related to
the status of mineralization.
Methods
The first population studied consisted of 13 male
and 12 female, randomly selected patients with
chronic uremia (mean age, 39.2 14.9 [SD] yr), who
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had been on maintenance hemodialysis an average of
35 months. All patients were dialyzed three times a
week against a dialysate calcium of 6.5 mg/dl. Fol-
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lowing selection of these patients, their charts were
reviewed for history of vitamin D therapy, and their
current skeletal x-ray films were quantitated accord-
ing to the method of Debnam et a! [10].
The second group studied was comprised of 17
consecutively encountered patients with primary
hyperparathyroidism. The group included 11 males
and 6 females (mean age, 55.7 11.3 [sDjj yr).
Each patient received one gram of oxytetracycline
per day in four divided doses for three days, immedi-
ately prior to transiliac biopsy with a trocar (I.D., 0.5
cm). On the day of biopsy, blood was obtained for
measurement of total calcium, phosphorus, alkaline
phosphatase, and immunoreactive parathyroid hor-
mone (iPTH) [11]. Bone biopsy was performed on
the uremic patients under local anesthesia, and dur-
ing parathyroidectomy on those with primary
hyperparathyroidism.
Each bone biopsy specimen, which consisted of
both cortices and intervening trabeculae, was fixed
in neutral buffered formalin for 24 hr, embedded in
methylmethacrylate, and cut in l0-m sections on a
sledge microtome (Jung, model K). Unstained sec-
tions were examined in a fluorescent microscope
(Leitz Ortholux) by a microscopist with no knowl-
edge of the source of the slide. Employing a filar
micrometer, we measured the width of the fluorescent
label at 25 points where present on straight portions
of trabeculae, as determined by random interception
of the cross hairs of the micrometer, and expressed
as the mean label width of each patient, and the mean
label width of the group. The maximum of each 25
measurements was identified in each patient as the
maximum label width; and the mean of these values,
as the average maximum label width of the group.
To compare the relative specificity of the tetracy-
cline-based measurements to those routinely evalu-
ated in nondecalcified thin sections of bone, a 5.0-
m section of each specimen was stained by a modi-
fication of the Goldner technique and histometrically
quantitated using an integrating eyepiece (Zeiss II) as
previously described 119]. The following nonfluores-
cent histologic parameters were evaluated: 1) per-
centage of relative osteoid volume (ROy), or the
percentage of trabecular bone matrix which is unmin-
eralized; 2) percentage of total osteoid surface
(TOS), or the percentage of trabecular surface cov-
ered by unmineralized bone matrix; 3) percentage of
osteoblastic osteoid surface (OOS), or the percent-
age of trabecular surface covered by osteoid lined by
plump osteoblasts; 4) number of osteoclasts per mm2
of cancellous space (OCL); and 5) percentage of
surface fibrosis (FIB), or the percentage of trabecu-
Jar surface in apposition to marrow fibrosis.
The differences in measured parameters between
groups were evaluated by Student's t test. In addi-
tion, correlations between the magnitudes of each
nonfluorescent parameter and the tetracycline-
based variables were examined. Any such relation-
ships were evaluated within the groups of biopsies of
patients with primary hyperparathyroidism or renal
failure, as well as those of uremic patients who had
been treated or untreated with vitamin D. They were
also evaluated among the biopsies of all 42 patients
considered as a single group.
Results
Clinical. Nine of the 25 patients with chronic renal
failure had been taking vitamin D for at least three
months. The dosage administered to seven patients
was 50,000 IU of vitamin D2 daily, while two patients
received an identical dose tn-weekly and bi-weekly,
respectively. There were no differences in the ages
nor the duration of dialytic therapy of the vitamin D
and non-vitamin D-treated patients.
There were distinctions between the circulating
biochemical parameters of these two groups, how-
ever (Table 1). The mean total calcium was higher (P
<0.05) and the phosphorus lower (P <0.05) in those
patients receiving ergocalciferol. Furthermore, while
circulating IPTH was increased in all patients with
chronic renal failure, it was more than four-fold
greater in those who had not received vitamin D2 (P
< 0.025). On the other hand, the skeletal x-rays of
the vitamin D-treated patients exhibited more
severe renal osteodystrophy (P <0.025).
Sixteen of the 17 patients with primary hyperpara-
thyroidism were hypercalcemic (Table 1). Eight
patients were hypophosphatemic, and seven had ele-
vated levels of circulating alkaline phosphatase. Cir-
culating iPTH levels were determined in all but one
patient and was increased in each, including the
individual with a normal serum calcium
concentration.
No patient with primary hyperparathyroidism
complained of symptoms referable to the skeletal
system. Seven patients, however, had radiographic
abnormalities. Five had generalized skeletal demin-
eralization, while two had evidence of subperiosteal
resorption. One of the two latter patients also had a
lesion consistent in appearance with osteitis fibrosa
cystica.
Histometric. The mean label width of the group of
patients with uremia was greater than twice that of
those with primary hyperparathyroidism (Table 2).
Whereas only six percent, or one of 17 primary
hyperparathyroid patients had mean label widths
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Table 1. Mean values SD of circulating biochemical parameters (at time of bone biopsy) of patient
groups studieda
CRF patients CRF patients
All patients treated with not treated P
Normal range with CRF vit. D with vit. D
atients with
PHP
Calcium, mgldl 9 to 10.5 9.9 1.4 10.7 1.5 9.5 1.0
Phosphorus, mgldl 2.5 5.0 5.0 1.5 4.1 1.2 5.5 1.5
Alkaline phosphatase, IU <100 84 54 83 72 84 45
iFTH, pJEq/ml <10 354 359 115 131 491 378
12.1 (J.
2.6 0.6
107 42
39 41
a Abbreviations used are: CRF, chronic renal failure; PHP, primary hyperparathyroidism; iPTH,
immunoreactive parathyroid hormone.
Table 2. Mean values SD of histometrically measured bone biopsy parameters of patient groups studied'
Osteoblastic Osteoclasts/mm2
Mean label Maximum Relative osteoid Total osteoid osteoid of cancellous
Patient group width label width volume, % surface, % surface, % space
Surface
fibrosis, %
PHP 5.94 2.35 15.5 4.81 8.56 4.35 44.6 17.6 8.93 7.47 1.06 0.77
vs. all CRF 12.4 10.9" 44.2 33.61 11.5 5.88 71.8 15.0' 5.39 5.79 1.06 1.02
2.68 6.86
10.2 15.3
PUP 5.94 2.35 15.5 4.81 8.56 4.35 44.6 17.6 8.93 7.47 1.06 0.77
vs. CRF (vit. D-treated) 7.30 4.5 21.5 15.0 10.8 6.95 69.1 l8.O5' 4.38 7.74 0.88 1.12
2.68 6.86
6.45 16.3
PHP 5.94 2.35 15.5 4.81 8.56 4.35 44.6 17.6 8.93 7.47 1.06 0.77
vs. CRF (no vit. D therapy) 15.5 12•5d 57.0 34.7' 11.9 5.39 73.3 13.5' 5.96 4.55 1.16 0.98
2.68 6.86
12.3 14.8
CRF (vit. D-treated) 7.30 4.5 21.5 15.0 10.8 6.95 69.1 18.05 4.38 7.74 0.88 1.12
vs. CRF(no vit. D therapy) 15.3 12.5 57.0 34.7' 11.9 5.39 73.3 13.5 5.96 4.55 1.16 0.98
6.45 16.3
12.3 14.8
a Abbreviations used are PHP, primary hyperparathyroidism; CRF, chronic renal failure.
b P < 0.025.
P < 0.010.
P <0.005.
i' <0.001.
greater than 10 rm, this was evident in 44% of
uremic patients (Fig. 1). The increased mean label
width of the uremic patients, relative to those with
primary hyperparathyroidism, was due entirely to
those who had not been treated with vitamin D. No
significant difference in mean label width existed
between the group of renal patients who had been
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Fig. 1. Distribution of mean label widths of patients with primary
hyperparathyroidism (solid) and renal friilure (dotted).
treated with vitamin D and individuals with primary
hyperparathyroidism (Table 2). In addition, 22.2%of
uremic patients treated with this compound had a
mean label width greater than 10 .rm, while this value
was exceded in the biopsies of 56.2% of untreated
patients with renal failure (Fig. 2).
St 60
50
40
30
20
10
Mean label width, pm0-5.0 5.1-10.0 10.-
Mean label width, pm
45.1-50.0
0-5.0 5.1-10.0 10.1—15.0 15.1- 45.1-50.0
Fig. 2. Distribution of mean label widths of patients with primary
hyperparathyroidism (solid), renal failure treated with vitamin D
(diagonal), and renal failure untreated with vitamin D (dotted).
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The average maximum label widths of the two
large groups were even more strikingly different than
the mean label widths. The average maximum label
width of all patients with uremia was approximately
three-fold greater than that of the patients with pri-
mary hyperparathyroidism (Table 2). Similar to the
mean label width, the relatively large magnitude of
the uremic average maximum label width was due
exclusively to measurements made in those untreat-
ed with vitamin D. Not only was there a significant
difference between the average maximum label
widths of the primary hyperparathyroid group and
the untreated uremic group, while no such distinc-
tion existed between the treated uremic and primary
hyperparathyroid patients, but the average maxi-
mum label width of the untreated uremic patients
was significantly greater than that of those patients
who had received vitamin D. Notable differences in
the distribution of the maximum label widths within
the two major groups were also present. Whereas no
patients with primary hyperparathyroidism had a
maximum label width greater than 30 m, this was
present in 60% of uremics (Fig. 3), and 75.1% of
those who had not received vitamin D (Fig. 4).
I I1ln
0-10.0 10.1-20.0 20.1-30.0 30.1-40.0 40.1-50.0 >50.0
Maximum label width, pm
Fig. 3. Distribution of maximum label widths of patients ii'ith
primary hyperpai-athvroidism (solid) and renal fidlure (dotted).
Nonfluorescent histologic features did not define
the two major groups as clearly as did the tetra-
cycline-based parameters. Only the percentage of tra-
becular surface covered by osteoid (TOS) was signif-
icantly different in the uremic and primary
hyperparathyroid patients (Table 2). In addition,
whereas average maximum label widths were signifi-
cantly different in the two uremic subgroups, no
nonfluorescent histologic feature distinguished those
patients with renal failure who had received vitamin
D from those who had not been treated with this
compound. Moreover, there were no correlations
between nonfluorescent and fluorescent morphome-
tric parameters in any group of patients.
Discussion
Nondecalcified histologic sections of bone are
indispensable for the morphologic evaluation of renal
osteodystrophy. Of major importance is that by the
use of these sections, one is able to distinguish
mineralized from nonmineralized bone matrix. Con-
sequently, it has become appreciated that the mor-
phologic diagnosis of osteomalacia necessitates his-
tologic demonstration of an excess quantity of
osteoid (hyperosteoidosis).
While investigators assume excessive osteoid is
pathognomonic of osteomalacia [12], hyperoste-
oidosis may theoretically represent an increased rate
of bone matrix deposition in face of a normal miner-
alization rate. Such a condition is believed by Sher-
rard et al to exist in uremic patients whose bone
biopsies exhibit a predominance of osteitis fibrosa
[13]:
The distinction between hyperosteoidosis due to a
mineralization defect and that secondary to an
increased rate of bone collagen synthesis may be
achieved by use of tetracyclines as fluorescent mark-
ers of bone mineralization [14]. These antibiotics are
characteristically deposited in newly synthesized
bone [1, 15—17]. Consequently, the tetracyclines
have become invaluable, in vivo markers of new
bone formation [3—81. As has been demonstrated by
Taylor and Frost [18], however, a finite quantity of
skeletal tissue exists at the interface of osteoid and
mineralized bone, which binds the antibiotic instan-
taneously, and therefore does not represent bone
mineralization which has occurred during its admin-
istration. Consequently, the total quantity of fluores-
cent bone present following a period of tetracycline
administration reflects the sum of bone which has
been mineralized during that period, and the instan-
taneously fluorescing zone.
This study demonstrates that the widths of single
fluorescent labels administered over a relatively
100
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0-10.0 10.1-20.0 20.1-30.0 30.1-40.0 40.1-50.0 >50.0
Maximum label width, pm
Fig. 4. Distribution of maximum label widths of patients with
primary hvperparathyroidism (solid) and renal failure treated with
vita mitt D (diagonal) and untreated with vitamin D (dotted).
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short period of time are distinct in uremic as com-
pared to primary hyperparathyroid bone. Further-
more, while one nonfluorescent histometric parame-
ter (TOS) is significantly different in the biopsies of
patients with primary hyperparathyroidism, as com-
pared to those with chronic renal failure, no correla-
tions exist between any fluorescent and nonfluores-
cent parameter. Consequently, the tetracycline label
width may reflect a phenomenon which cannot be
appreciated by examining nonfluorescent histologic
sections.
As the fluorescent band represents the sum of
bone which has been mineralized during the period
of tetracycline labeling and the instantaneously flu-
orescing zone, the magnitude of the label width in
uremia can only be related to 1) an accelerated rate
of bone mineralization. 2) prolongation of the circu-
lating half-life of tetracycline, and/or 3) a wide
instantaneously fluorescing zone. A decreased rate
of bone mineralization exists in chronic renal failure
[19, 201, however, and it is therefore unlikely that
accelerated bone formation has occurred in our
uremic patients. In addition, while the circulating
half-lives of the tetracyclines are prolonged in ure-
mia [21], the degree of renal insufficiency was identi-
cal in both our vitamin D and nonvitamin D-tieated
patients, despite differences in label width. Further-
more, abnormally wide labels occur in hypophospha-
temic osteomalacia [91, and in vitamin D deficient
rats [22] in the absence of renal failure. Therefore,
the wide fluorescent labels encountered in our urem-
ic patients are most likely representative of the
instantaneously fluorescing zone. As such, the use of
a continuously administered (single) tetracycline
marker to measure skeletal formation will overesti-
mate the quantity of matrix mineralized, particularly
in states with a wide instantaneously fluorescing
zone. This problem may be circumvented by admin-
istering time-spaced (double) fluorescent markers, as
proposed by Frost [23]. This technique rests on the
assumption that skeletal mineralization is in a steady
state and that the width of the first instantaneously
fluorescing zone equals that of the second. As such,
tissue mineralized from the middle of administration
of the first label to the middle of the second is
reflected by the quantity of bone encompassed by the
midpoints of the fluorescent bands.
In lamellar bone, tetracycline is largely chelated at
the interface of osteoid and mineralized bone [24],
variously called the calcification or mineralization
front. In this regard, we have not observed in these
or other histologic sections of bone labeled with the
antibiotic, the diffuse, low-level fluorescence report-
ed in deep interstitial lamellae by Urist and Ibsen
[15] and Harris, Jackson, and Jowsey [16]. It is of
interest that the latter investigators [16] observed
this phenomenon only following administration of
doses of tetracycline far in excess of those used in
this study. Furthermore, they describe diffuse, inter-
stitial, low-level fluorescence exclusively in areas
where some degree of increased calcium 45 uptake is
autoradiographically apparent. This finding indicates
that while matrix synthesis may have ceased in these
foci, the rate of mineral deposition is greater than in
surrounding deep bone.
The thickness of our histologic sections may also
relate to our failure to observe diffuse, low-level
interstitial fluorescence. Urist and Ibsen [15] and
Harris et al [16] studied sections five to ten times
thicker than those prepared in our laboratory, which
would be expected to result in greater sensitivity to
fluorescence. Furthermore, as osteocytes are capa-
ble of mineralization activity [25], perilacunar, tetra-
cycline fluorescence [16] outside of the plane of
focus may contribute to the diffuse interstitial phe-
nomenon observed in thick sections.
Accumulated evidence suggests the mineral phase
at the calcification front is probably amorphous cal-
cium phosphate [261, the form in which bone mineral
is most likely deposited [271. With time, amorphous
calcium phosphate is transformed into crystalline
hydroxyapatite, which characterizes the deeper por-
tions of the skeleton [27]. As tetracycline is incapa-
ble of binding to normal deep bone in quantities
sufficient to produce the degree of fluorescence pres-
ent in the biopsies of our patients, it is reasonable to
assume that the instantaneously fluorescing zone
reflects amorphous calcium phosphate existing at the
time of tetracycline administration. Therefore, it is
likely that the quantity of amorphous calcium phos-
phate at the mineralization front of patients with
uremia is greater than in those with primary hyper-
parathyroidism. This is consistent with the demon-
stration of a delay in mineral maturation in experi-
mental uremia by Russell, Termine, and Avioli [28].
The failure of nonfluorescent histometric parame-
ters to reflect fluorescent label width probably relates
to the inability of currently employed histologic
stains to distinguish immature from mature bone
mineral. For example, woven bone which fluoresces
diffusely following tetracycline administration [29],
and therefore probably contains increased quantities
of amorphous calcium phosphate, appears tinctorial-
ly similar to lamellar bone when stained by the Gold-
ner technique. In this regard, the data presented in
this study may call for redefinition of the histologic
manifestations of osteomalacia. This defect has been
characterized by an excess of osteoid seams, few of
which assume a tetracycline label [30]. As has been
demonstrated in this laboratory [9] as well as in
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others [13], states of deficient mineralization, includ-
ing chronic renal failure [13], exist in which a normal
percentage of such seams assume a tetracycline
label, albeit wide and irregular. This abnormality
suggests that there are at least two kinetic defects of
mineralization associated with osteomalacia. Defi-
cient rates of deposition of amorphous calcium phos-
phate may be reflected by an absence of fluorescence
at the mineralizing front, while wide fluorescing
fronts may represent a delay in the maturation of
amorphous calcium phosphate to its crystalline
phase. The relative normalization of the fluorescent
label width occurring in uremic patients treated with
vitamin D suggests this compound may accelerate
the rate of mineral maturation in renal osteodystro-
phy, as has been shown experimentally by Russell et
al [31]. As more radiographic evidence of renal
osteodystrophy existed in the vitamin D-treated
patients than in those of patients not receiving ergo-
calciferol, despite lower levels of circulating iPTH
and phosphorus, fluorescent histologic parameters
are earlier harbingers of skeletal improvement than
x-ray examination. Furthermore, despite longitudi-
nal studies demonstrating amelioration of renal
osteodystrophy, as evaluated by nonfluorescent his-
tology following treatment with analogs of vitamin D
[32, 33], our data suggest the sensitivity of these
nontetracycline-based parameters, as representative
of vitamin D-induced effect on the uremic skeleton,
may not be as great as fluorescent label width. Con-
sequently, histologic evaluation of the state of bone
mineralization in uremia may require measurement
of fluorescent label width as well as mineralization
rate and osteoid volume.
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